Drug intelligence / Profile preview

VM-PSY-002

Development stage: Unknown
Lead developer: VivaMed
Modality: Small Molecules

Overview

VM-PSY-002 is a small-molecule combination therapy being developed by VivaMed BioPharma for the treatment of stimulant use disorder, specifically focusing on cocaine use disorder. Currently in Phase 2 clinical development, the drug aims to provide a pharmacological intervention for stimulant addiction, a field with significant unmet medical needs and no currently approved medications. While the specific active ingredients and molecular targets of the combination have not been publicly disclosed by the company, the candidate is part of a broader psychiatric pipeline targeting substance use disorders.

Beyond the preview

Go deeper on VM-PSY-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VM-PSY-002.

Explore the full profile